VivoSim Labs (0R02) Share Price & Analysis

0R02 Stock Chart & Stats

$0.23$0.00(0.00%)

At close: Oct 30 4:30 PM GMT

Day’s Range: $0.23 - $0.23
52-Week Range: $0.23 - $3.36
Previous Close: $0.23
Volume: 0
Average Volume (3M): 707
Market Cap: $2.56M
Enterprise Value: -$764.00B
Total Cash (Recent Filing): $1.67M
Total Debt (Recent Filing): $316.00K
Price to Earnings (P/E): ―
Beta: 0.87
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

VivoSim Labs News

VivoSim Labs Optimizes Headquarters Lease and Space Usage

An update from VivoSim Labs ( ($VIVS) ) is now available. On October 13, 2026, Organovo, Inc., a subsidiary of VivoSim Labs, entered a second amendment to its lease for

2w ago8K VIVS

VivoSim celebrates updated FDA regulations in non-animal testing methods

VivoSim (VIVS) celebrated the FDA direct final rule updating its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products

3w agoVIVS 4OR

VivoSim Labs Shareholders Approve Governance and Capital Changes

VivoSim Labs ( ($VIVS) ) has issued an update. On September 30, 2026, VivoSim Labs, Inc. held its 2026 Annual Meeting of Stockholders, where a quorum of 37.26% of outstanding

3w ago8K VIVS

VivoSim Labs Faces Nasdaq Minimum Bid Price Deficiency

The latest announcement is out from VivoSim Labs ( ($VIVS) ). On August 17, 2026, VivoSim Labs received notice from Nasdaq that its common stock had failed to meet the

2M ago8K VIVS

VivoSim regains compliance with Nasdaq

VivoSim (VIVS) announced that it received notice from Nasdaq indicating that the company has regained compliance with Nasdaq Listing Rule 5550 which requires registrants to maintain a minimum stockholders’ equity

2M agoVIVS 4OR

VivoSim files to sell 9.41M shares of common stock for holders

16:18 EDT VivoSim (VIVS) files to sell 9.41M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

3M agoVIVS 4OR

VivoSim Labs Sets 2026 Annual Shareholder Meeting Date

VivoSim Labs ( ($VIVS) ) has provided an update. On July 30, 2026, VivoSim Labs, Inc. announced that its 2026 Annual Meeting of Stockholders will be held on September 30,

3M ago8K VIVS

VivoSim Labs Addresses Nasdaq Listing Compliance Concerns

VivoSim Labs ( ($VIVS) ) has provided an announcement. On July 20, 2026, VivoSim Labs received notice from Nasdaq that it no longer met the required minimum of $2.5 million

3M ago8K VIVS

VivoSim enters China with first commercial sales of NAMkind testing services

VivoSim (VIVS) announced its first commercial sales in China, opening a new market for its NAMkind testing services. VivoSim delivers both toxicology and efficacy testing built on its 3D human

3M agoVIVS 4OR

VivoSim Labs Announces $4 Million Private Placement Financing

VivoSim Labs ( ($VIVS) ) has shared an update. On July 16, 2026, VivoSim Labs entered into a securities purchase agreement with a single healthcare-focused institutional investor for a $4.0

3M ago8K VIVS

Why Is Penny Stock VivoSim Labs (VIVS) Up Today?

VivoSim Labs stock was on the rise Wednesday after it received a new milestone payment from Eli Lilly.

3M agoLLY VIVS

VivoSim receives $5M milestone payment from Eli Lilly

VivoSim (VIVS) announced that it has received a $5M payment from Eli Lilly (LLY). In association with its former inflammatory bowel disease drug program developed previously and sold outright to

3M agoLLY VIVS

VivoSim sees FY27 revenue up over 500%

The company said, “VivoSim (VIVS) further announced that it anticipates significant revenue growth in Fiscal Year 2027 given its progress in marketing contract research services using NAMs models to pharmaceutical

3M agoVIVS 4OR

VivoSim Labs Delays Annual SEC Filing

VivoSim Labs ( ($VIVS) ) has released a notification of late filing. VivoSim Labs, Inc. has filed a Form 12b-25 to notify investors that its Annual Report on Form 10-K

4M agoVIVS 4OR

0R02 FAQ

What was VivoSim Labs’s price range in the past 12 months?

VivoSim Labs lowest share price was $0.23 and its highest was $3.36 in the past 12 months.

What is VivoSim Labs’s market cap?

VivoSim Labs’s market cap is $2.56M.

When is VivoSim Labs’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were VivoSim Labs’s earnings last quarter?

VivoSim Labs released its earnings results on Aug 08, 2019. The company reported -$1 earnings per share for the quarter.

Is VivoSim Labs overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does VivoSim Labs pay dividends?

VivoSim Labs does not currently pay dividends.

What is VivoSim Labs’s EPS estimate?

VivoSim Labs’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does VivoSim Labs have?

VivoSim Labs has 16,586,494 shares outstanding.

What happened to VivoSim Labs’s price movement after its last earnings report?

VivoSim Labs reported an EPS of -$1 in its last earnings report. Following the earnings report the stock price went same ―.

Which hedge fund is a major shareholder of VivoSim Labs?

Currently, no hedge funds are holding shares in GB:0R02

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

VivoSim Labs

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

VivoSim Labs (0R02) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Bearish
Overall Consensus	3	14
Technical Analysis	2	3
Moving Averages	1	11

Technical Analysis >

Similar Stocks

Stocks similar to GB:0R02
Company	Price & Change	Follow
CLGNCollplant Holdings
BBLGBone Biologics
CELZCreative Medical Technology Holdings
VRAXVirax Biolabs Group Ltd. Class A
NEXRNexera Technologies

Compare GB:0R02 Stocks >

Ownership Overview

0.67% Insiders
0.21% Mutual Funds
0.07% Other Institutional Investors
98.96% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

0R02 Stock Chart & Stats

VivoSim Labs News

VivoSim Labs Optimizes Headquarters Lease and Space Usage

VivoSim celebrates updated FDA regulations in non-animal testing methods

VivoSim Labs Shareholders Approve Governance and Capital Changes

VivoSim Labs Faces Nasdaq Minimum Bid Price Deficiency

VivoSim regains compliance with Nasdaq

VivoSim files to sell 9.41M shares of common stock for holders

VivoSim Labs Sets 2026 Annual Shareholder Meeting Date

VivoSim Labs Addresses Nasdaq Listing Compliance Concerns

VivoSim enters China with first commercial sales of NAMkind testing services

VivoSim Labs Announces $4 Million Private Placement Financing

Why Is Penny Stock VivoSim Labs (VIVS) Up Today?

VivoSim receives $5M milestone payment from Eli Lilly

VivoSim sees FY27 revenue up over 500%

VivoSim Labs Delays Annual SEC Filing

0R02 FAQ

Company Description

VivoSim Labs

VivoSim Labs (0R02) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium